All posts by student

Weekly genetics review: Dramatic increase seen in AI use – Beef Central

THE use of artificial insemination in Australian beef herds is accelerating dramatically, and surprisingly the biggest increase is being seen in commercial herds.

Beef seedstock herds have traditionally been the biggest users of AI as they attempt to more efficiently multiply superior genetics.

Bovine semen marketing industry veteran Bill Cornell, who for the past 14 years has headed the beef division of ABS Australia, said unit sales of beef semen for the company had doubled over the past two years, and there was no sign of the trend abating.

Bill Cornell

Its just been amazing the response in terms of dollar turnover domestically for beef semen for us, he said.

Fixed time AI and confidence in Breedplan are the main reasons commercial producers are prepared to take on AI programs aimed at introducing superior genetics into their herds.

While the swing to AI may raise questions as to the number of bulls required for natural matings, back-up bulls are still required and seedstock producers will still be rewarded when they breed a potential donor bull combining superior phenotype and Breedplan figures.

And in more good news for Australian seedstock producers, two out of every three beef semen units sold in Australia today is produced domestically. In addition, Australia now exports more beef semen than it imports.

Australia has developed a strong reputation worldwide as the developer of superior genetics, the result of the preparedness of Australian seedstock producers over many years to use the best genetics available globally and Australias highly-regarded Breedplan performance recording system that can describe those genetics, Mr Cornell said.

Australian-based semen producing companies are buying, leasing or making partnership arrangements with more and more Australian seedstock producers to generate product to satisfy increasing demand.

At the top end was the sale of the Angus bull Millah Murrah Kingdom for $150,000 a couple of years ago, to a syndicate comprising Angus studs Ascot, Gilmandyke and Witherswood, and ABS Australia. The stud syndicate members have the paddock rights, while ABS Australia controls the semen rights world-wide.

Kingdoms sales have gone really well, not only in Australia but to several overseas countries. There are calves on the ground showing great promise, said Mr Cornell.

ABS Global and sister company Genus is the worlds largest provider of domesticated livestock semen and also head the lists as the largest providers of beef bovine semen.

Fixed time AI is all the rage in commercial beef herds performing artificial breeding programs, meaning no more tedious and often erroneous heat detection.

While overall well-being, being properly vaccinated, well managed and on a rising plane of nutrition are still important in getting females in calf in AI programs, the seven day co-sync program results in good conception rates with only three visits to the yards.

Australia is now punching above its weight in the semen production industry relative to its beef herd size

The program can differ slightly for heifers and cows, but basically it comprises CIDR (Controlled Internal Drug Release, based on progesterone) input on day 1, seven days later remove the CIDR and treat with prostaglandin and 2.5 days later AI and treat with GNRH.

ABS Globals conception average is 58pc to the first AI, the company says. Producers using the system for the first time may achieve a 45-50pc conception rate while the experienced operator on their fifth or sixth run can achieve up to 65pc success rates.

Australia is now punching above its weight in the semen production industry relative to its beef herd population, and now sells semen to around 22 countries, Mr Cornell said.

We now export more semen than we import, he said.

Mr Cornell also listed Australias disease-free status as a reason for Australias attraction as a semen supplier.

Of all the countries that we export to, the United Kingdom would be the hardest because of their IBR requirements, he said.

Many bulls fail the UKs IBR test, but they are mainly the older bulls. If a bull is 12-14 months old and been running in groups of similarly aged bulls, they are generally OK.

But older bulls that have been out in the paddock with cows have a bigger chance of testing positive. Interestingly some farms and even some districts dont seem to test positive for IBR, Mr Cornell said.

Excerpt from:
Weekly genetics review: Dramatic increase seen in AI use - Beef Central

Do Parents Have a Right to Sue Over Their Kids’ Genetics? – Gizmodo

An animatronic baby at the London Science Museum. Photo: Getty

Its a nightmare scenario straight out of a primetime drama: a child-seeking couple visits a fertility clinic to try their luck within-vitro fertilization, only to wind up accidentally impregnated by the wrong sperm.

In a fascinating legal case out of Singapore, the countrys Supreme Court ruled that this situation doesnt just constitute medical malpractice. The fertility clinic, the court recently ruled, must pay the parents 30% of upkeep costs for the child for a loss of genetic affinity. In other words, the clinic must pay the parents child support not only because they made a terrible medical mistake, but because the child didnt wind up with the right genes.

At a time when rapidly advancing science and technology puts things like genetically engineering embryos to prevent disease in the realm of reality, the case sets an intriguing precedent. First, it places a monetary value on the amount of DNA that a child shares with their parents. And it suggests that the base genetic makeup of a child can actually be wrong.

Its suggesting that the child itself has something wrong with it, genetically, and that it has monetary value attached to it, Todd Kuiken, a senior research scholar with the Genetic Engineering and Society Center at North Carolina State University, told Gizmodo. They attached damages to the genetic makeup of the child, rather than the mistake. Thats the part that makes it uncomfortable. This can take you in all sort of fucked up directions.

In the court case in question, the couple underwent a successful IVF procedure at Thomson Medical Centre in Singapore and gave birth to a healthy baby girl in 2010. Soon, though, the couple suspected something was amiss. Their daughters features seemed markedly different from their own, and different from those of their first child. A genetic test soon confirmed that their daughter was related to her mother, but not her father. The center then confirmed a mistake: An anonymous donors sperm had accidentally been used to inseminate the mothers egg. The couple were of Chinese and German heritage. But the genetic father of their daughter was Indian.

The couple sued the medical center, seeking damages including child care costs through the age of 21. The court ultimately granted those damages, setting a new legal standard. Whether were related to our kids, the court found, is highly valued in societyit is, after all, the reason so many people spend so much time and money on IVF procedures in the first place.

Interestingly, the court settled on establishing a new category of lossgenetic affinityin order to avoid sending the message that the childs birth itself was a mistake, a basis upon which courts often deny wrongful birth claims. These cases often arise when, say, one parent has been sterilized but a couple gets pregnant anyway. In a wrongful fertilization case in New York, the state supreme court found that it cannot be said, as a matter of public policy, that the birth of a healthy child constitutes a harm cognizable at law.

In the Singaporean case, however, the court disagreed. Parents, they found, have a legal right to share traits like eye color and skin color with their children. The court made that determination relying on an obscure 1999 law review article that argues parents have an interest in having children with whom they share symbolically identifying traits. This on its own raises all kinds of questions.

Does this mean that adopted children are more or less valuable? said Kuiken. Or you can imagine a divorce scenario in which child support is determined by what percentage of genes a parent shares with the child. Or blame is placed on one parent for a child inheriting a particular disease.

According to Eleonore Pauwels, a science policy expert at the Wilson Center, the ruling defines kinship as something thats only skin deep. Defining someone by their genotype is the most reductionist way you can look at an identity, said Pauwels told Gizmodo. Genetic affinity is such a superficial concept. It questions the very basis of what makes someone a parent.

But the problems this ruling raises extend beyond genetic affinity. In creating this new category of loss, the court sought to avoid suggesting there was something inherently wrong with the childs birth, but the ruling suggests specific genetic traits are more valuable than others all the same.

Pauwels said that for her this brings to mind one particular quote in the 1997 sci-fi film Gattaca: They used to say that a child conceived in love has a greater chance of happiness. They dont say that anymore.

This sets the stage for much more personalized, genome-level discrimination, she said.

What if, for example, a mother found out she had a devastating mitochondrial disease a underwent the controversial three-parent baby technique to avoid passing that DNA on to her child, and it failed? Could she sue for the childs DNAits existencebeing incorrect? Further down the line, should science and the law ever allow parents to select specific genetic traits, could you sue if your kid had the wrong eye color, or a lower-than-expected IQ? If you engineered a child, and it wound up having more genetic affinity with one parent than the other, does that constitute some kind of loss?

This opens up a dangerous box that when we start talking about editing the human genome, Kuiken said. A ruling like this places value on the specific genetic makeup of a child.

Obviously, the parents in the Singaporean case were at the wrong end of a devastating medical mistake. But in ruling that the genes their child wound up with warrant financial reward in a court of law, the court is placing a value on her genes, whether intended or not. And that is the top of one very slippery slope.

View original post here:
Do Parents Have a Right to Sue Over Their Kids' Genetics? - Gizmodo

IUMS Hosting Reproductive Health Congress – Financial Tribune

An international congress on reproductive health organized by the Iranian Society of Embryology & Reproductive Biology (ISERB) will be held April 19-21 at the Iran University of Medical Sciences in Tehran. The 2nd International Congress on Reproductive Health and Childbearing (ICRHC) will provide a platform for exchange of data, information and scientific ideas in the field, icrhc-iserb.ir website reported. Sixteen panels will be held during the 3-day event, including medication therapy to enhance sperm quality, sexual health and strategies to improve marital relationships, endometriosis and POS (polycystic ovarian syndrome) treatment, screening embryo health before implantation in infertility treatment, social aspects of assisted reproduction, availability of infertility medications in Iran and their levels of effectiveness, and stem cells. Health experts who will address the confab are head of Food and Drug Administration Rasoul Dinarvand, deputy health minister Reza Malekzadeh, head of Avicenna Infertility Treatment Center Behzad Qorbani, head of ISERB Mohammad Mehdi Akhundi, head of FDAs Food and Drug Control Labs Hossein Rastegar, and head of Royan Research Institute Hamid Gourabi. Participants include doctors in reproduction biology and medical sciences and clinical experts in gynecology, obstetrics and infertility, urology, endocrinology and metabolism as well as in nutrition, midwifery, nursing, laboratory science. Besides, experts in paramedical sciences, veterinary medicine, sociology, psychology, law and ethics and general practitioners, will attend the congress. Introducing the latest scientific achievements in the field of reproductive health, motivating researchers in different branches of biology to apply biotechnology in reproduction issues, training physicians in diagnosis and treatment of different diseases, and creating research teams for interdisciplinary research, are the main goals of the congress.

Here is the original post:
IUMS Hosting Reproductive Health Congress - Financial Tribune

New cocktail encourages stem cell diversification – Laboratory News – Lab News

A team of international scientists have discovered a chemical cocktail that enables stem cells to regrow any type of tissue.

The study highlights how totipotent the ability to develop into the placenta and omnipotent stem cells can be derived from both human and mouse embryos. Modelling early development processes and diseases affecting embryo implantation are two techniques that could be improved as a result of this discovery.

Professor Carlos Izpisua Bemonte, from the Salk Institute and co-author of the paper published in Cell, said: During embryonic development, both the fertilised egg and its initial cells are considered totipotent, as they can give rise to all embryonic and extra-embryonic lineages. However, the capture of stem cells with such developmental potential in vitro has been a major challenge in stem cell biology. This is the first study reporting the derivation of a stable stem cell type that shows totipotent-like bi-developmental potential towards both embryonic and extra-embryonic lineages.

Before the cocktail was created, the scientists screened chemical compounds that support pluripotency, discovering a combination of four chemicals and a growth factor was most effective. The cocktail stabilised immature human pluripotent cells, enabling a greater possibility of creating chimeric cells in developing murine embryos.

With the same cocktail was applied to murine cells, the team found that the new stem cells could not only produce embryonic tissue, but also form extra-embryonic cells, which then became the placenta or amniotic sac. These new stem cells could give rise to an entire adult mouse, which the researchers have said is unprecedented and have called extended pluripotent stem (EPS) cells.

Jun Wu, a senior scientist at Salk and first author of the paper, said: The discovery of EPS cells provides a potential opportunity for developing a universal method to establish stem cells that have extended developmental potency in mammals. Importantly, the superior interspecies chimeric competency of EPS cells makes them especially valuable for studying development, evolution and human organ generation using a host animal species.

The researchers next step will be to test if these EPS cells could be used in transgenic animal models and creating replacement product organs. EPS cells could work in tandem with research published at the beginning of the year in Cell, on interspecies chimeras. The team reported their success in growing a rat pancreas, heart and eyes in a developing mouse. Human cells and tissues were also grown in early-stage pig and cattle embryo, showing that an animal host could maybe grow organs for transplant.

Link:
New cocktail encourages stem cell diversification - Laboratory News - Lab News

Biochemistry Analyzers Market: Capacity, Production, Revenue … – MilTech

United States Biochemistry Analyzers market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Biochemistry Analyzers Market is expected to witness growth of international market with respect to advancements and innovations including development history, competitive analysis and regional development forecast.

The report starts with a basic Biochemistry Analyzers market overview. In this introductory section, the research report incorporates analysis of definitions, classifications, applications and industry chain structure.

Biochemistry Analyzers Market split by product type,with production, revenue, price, market share and growth rate of each type, can be divided into

Biochemistry Analyzers Market split by application,report focuses on consumption, market share and growth rate of Biochemistry Analyzers in each application and can be divided into

Browse more detail information about Biochemistry Analyzers Market at:http://www.360marketupdates.com/10582066

To begin with, the report elaborates the Biochemistry Analyzers Market overview. Various definitions and classification of the industry, applications of the industry and chain structure are given. Present day status of the Biochemistry Analyzers Market in key regions is stated and industry policies and news are analysed.

Following are the key players covered in this Biochemistry Analyzers Market research report:

And Many Others

Get a PDF Sample of Biochemistry Analyzers Market Research Report at:http://www.360marketupdates.com/enquiry/request-sample/10582066

After the basic information, the Biochemistry Analyzers Market report sheds light on the production. Production plants, their capacities, global production and revenue are studied. Also, the Biochemistry Analyzers Market growth in various regions and R&D status are also covered.

Following are Major Table of Content of Biochemistry Analyzers Industry:

Have any query? Ask our expert @ http://www.360marketupdates.com/enquiry/pre-order-enquiry/10582066

Scope of the Biochemistry Analyzers Industry on the basis of region:

Additionally, type wise and application wise consumption figures are also given. With the help of supply and consumption data, gap between these two is also explained.

To provide information on competitive landscape, this report includes detailed profiles of Biochemistry Analyzers Market key players. For each player, product details, capacity, price, cost, gross and revenue numbers are given. Their contact information is provided for better understanding.

View post:
Biochemistry Analyzers Market: Capacity, Production, Revenue ... - MilTech

Is Cristina Coming Back to Grey’s Anatomy? | POPSUGAR … – POPSUGAR

How has Grey's Anatomy managed to survive without badass cardiothoracic surgeon Dr. Cristina Yang for the last three seasons? Well, the popular medical drama has devoted quite some time to exploring Meredith's often precarious yet devoted sisterly bonds to Maggie and Amelia. As much as we love this new dynamic, there's no one quite like Mer's unapologetic soul sister or "person," as Mer puts it. From the pilot episode to Cristina's departure in season 10, Meredith and Cristina grow together, rising through the ranks from clueless interns to fearless attendings as they support each other through the worst of times. And we really do mean the worst of times: shootings, plane crashes, you name it.

Last Summer, Sandra Oh, the talented actress behind Cristina, sparked some hope in Grey's fans. She tweeted a picture with her Grey's Anatomy ex-husband Kevin McKidd, who plays trauma surgeon Dr. Owen Hunt, and former Grey's Anatomy screenwriter Tony Phelan.

Was it a merely a benign gathering of old chums, or were they discussing some Grey's business? It's most likely the former, but no one ever really knows when it comes to Shondaland. After all, the show has featured cameos from past main cast actors, like Kate Walsh and Isaiah Washington. On the matter of Cristina's return, McKidd casually commented in a recent interview that he'd "love it if she came back," and that he thinks "she might eventually for fun, for maybe a couple of episodes."

With Amelia and Owen's marriage on the rocks in season 13, some of us are speculating that Oh may return to add a plot twist or some unprecedented drama. Cristina is killing it in her career right now in Switzerland, and we couldn't be happier for her . . . but we wouldn't necessarily object to her return.

While promoting her new comedy film Catfight on Access Hollywood Live, Oh said that she doesn't think she'll come back to Grey's Anatomy, but gave a more evasive and uncertain answer about the possibility of returning for the series finale. Hinting that she had previously talked to showrunner Shonda Rhimes about it, Oh said: "I just don't know. It would just have to feel right." That's not a no!

We don't definitively know whether or not Cristina will be coming back, but if Oh does come back, it'll likely be a cameo or guest star appearance rather than a recurring role. If you miss seeing Oh on prime-time television, she'll be guest starring as a social worker in a three-episode story arc in the ABC series American Crime. For now, we'll just be rewatching throwback Grey's episodes and crying over this brilliant character brought to life by Oh's tour-de-force performance.

Fill Out Our Oscar Ballot For a Chance to Win $1,000!

by Maggie Pehanick 2/24

10 Celebrities You Didn't Know Had Oscars

by Kelsie Gibson 2/25

Who Will Win the 2017 Oscars? Our Predictions

by Shannon Vestal Robson 2/24

Oscars Movie Challenge: Use Our Checklist as You See All the Movies!

by Shannon Vestal Robson 2/26

Here's the Printable Oscars Ballot You Need For This Year's Show

by Shannon Vestal Robson 2/26

New York Fashion Week's Most Important Moments

by Sarah Wasilak 2/18

POPSUGAR, the #1 independent media and technology company for women. Where more than 75 million women go for original, inspirational content that feeds their passions and interests.

See the rest here:
Is Cristina Coming Back to Grey's Anatomy? | POPSUGAR ... - POPSUGAR

Why students are loving Coffs’s world-class facility – Coffs Coast Advocate

WHEN Stephan Soule began hosting School Engagement Activities (SEA) at Southern Cross University's National Marine Science Centre (NMSC) nine years ago, little did he know it would become one of the most successful programs of its kind in regional Australia.

The curriculum-based learning activities offered by the program enable students from Kindergarten to Year 12 to engage in hands-on learning at the Solitary Islands Aquarium, with behind-the-scenes exposure to one of the country's best marine research facilities.

Mr Soule said the SEA program not only attracted students from the Coffs region, but school groups travel from as far west as Armidale and Tamworth for week-long excursions on the Coast, when some students see the beach for the first time.

"Unlike students in big metropolitan cities, students in regional areas don't usually have access to museums and specialised facilities to gain more information and insight with enhanced learning activities to fill the gaps in the subjects they're studying. This can be a big disadvantage compared to their city counterparts," said Mr Soule, the Community Outreach and Education Program Manager at NMSC.

"But this is a fantastic world-class facility that teachers and students in the region can dip into, while drawing on the expertise of our researchers and qualified lecturers. No other regional hub in NSW has facilities like this."

The National Marine Science Centre is part of Southern Cross University's School of Environment, Science and Engineering, boasting one of Australia's best marine research facilities and a flow-through seawater system that supplies high quality seawater to labs, tank farm, hatchery and the aquarium.

Mr Soule said the Solitary Islands Aquarium featured marine life from the local area and hosted more than 12,000 visitors annually, including 2500 students in 80 school groups through the SEA program last year.

There are 12 curriculum-based activities teachers can nominate to take part in, including a handful of field activities such as studying the ecology of rocky shores, sandy beaches, and mangrove ecosystems, as well as the human impact on the environment.

"The laboratory-based activities include learning about fish biology through dissection, climate change and ocean acidification and marine taxonomy. Students even get a first-hand experience of breeding sea urchins during our embryology activity," he said.

"The program has developed into an important part of a number of school programs, with some teachers incorporating it into their programs every year.

"By bringing students to this facility, we also demonstrate what a career in marine science looks like, and some go on to study science through Southern Cross University at the National Marine Science Centre."

The Solitary Islands Aquarium is open to the public every Saturday and Sunday and every day during the school holidays. More information, including the SEA program can be found HERE.

See the original post here:
Why students are loving Coffs's world-class facility - Coffs Coast Advocate

Global 2017 Drug Delivery in Central Nervous System Diseases Technologies, Markets and Companies Report … – GlobeNewswire (press release)

April 17, 2017 12:36 ET | Source: Research and Markets

Dublin, April 17, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies" to their offering.

The delivery of drugs to central nervous system (CNS) is a challenge in the treatment of neurological disorders. Drugs may be administered directly into the CNS or administered systematically (e.g., by intravenous injection) for targeted action in the CNS. The major challenge to CNS drug delivery is the blood-brain barrier (BBB), which limits the access of drugs to the brain substance.

Advances in understanding of the cell biology of the BBB have opened new avenues and possibilities for improved drug delivery to the CNS. Several carrier or transport systems, enzymes, and receptors that control the penetration of molecules have been identified in the BBB endothelium. Receptor-mediated transcytosis can transport peptides and proteins across the BBB. Methods are available to assess the BBB permeability of drugs at the discovery stage to avoid development of drugs that fail to reach their target site of action in the CNS.

Many of the new developments in the treatment of neurological disorders will be biological therapies and these will require innovative methods for delivery. Cell, gene and antisense therapies are not only innovative treatments for CNS disorders but also involve sophisticated delivery methods. RNA interference (RNAi) as a form of antisense therapy is also described.

The role of drug delivery is depicted in the background of various therapies for neurological diseases including drugs in development and the role of special delivery preparations. Pain is included as it is considered to be a neurological disorder. A special chapter is devoted to drug delivery for brain tumors. Cell and gene therapies will play an important role in the treatment of neurological disorders in the future.

The method of delivery of a drug to the CNS has an impact on the drug's commercial potential. The market for CNS drug delivery technologies is directly linked to the CNS drug market. Values are calculated for the total CNS market and the share of drug delivery technologies. Starting with the market values for the year 2016, projections are made to the years 2021 and 2026. The markets values are tabulated according to therapeutic areas, technologies and geographical areas. Unmet needs for further development in CNS drug delivery technologies are identified according to the important methods of delivery of therapeutic substances to the CNS. Finally suggestions are made for strategies to expand CNS delivery markets. Besides development of new products, these include application of innovative methods of delivery to older drugs to improve their action and extend their patent life.

Profiles of 76 companies involved in drug delivery for CNS disorders are presented along with their technologies, products and 99 collaborations. These include pharmaceutical companies that develop CNS drugs and biotechnology companies that provide technologies for drug delivery. A number of cell and gene therapy companies with products in development for CNS disorders are included. References contains over 420 publications that are cited in the report. The report is supplemented with 53 tables and 13 figures.

Key Topics Covered:

Executive Summary

1. Basics of Drug Delivery to the Central Nervous System

2. Blood Brain Barrier

3. Methods of Drug Delivery to the CNS

4. Delivery of Cell, Gene and Antisense Therapies to the CNS

5. Drug Delivery for Treatment of Neurological Disorders

6. Drug delivery for brain tumors

7. Markets for Drug Delivery in CNS Disorders

8. Companies

9. References

For more information about this report visit http://www.researchandmarkets.com/research/qlbkw6/drug_delivery_in

Related Articles

Research and Markets Logo

LOGO URL | Copy the link below

Formats available:

Read the original here:
Global 2017 Drug Delivery in Central Nervous System Diseases Technologies, Markets and Companies Report ... - GlobeNewswire (press release)

Chlortetracycline Hydrochloride Market 2017 Fujian Fukang Pharmaceutical, Pucheng Chia Tai Biochemistry – TechAnnouncer (press release)…

The Global Chlortetracycline Hydrochloride Market 2017 Industry Research Report focused on global and regional market, major manufacturers, as well as the current state of the Chlortetracycline Hydrochloride industry. First, Global Chlortetracycline Hydrochloride Industry 2017 report analyzed the basic scope of this industry like definition, specification, classification, application, industry policy, news analysis and Chlortetracycline Hydrochloride industry chain structure.

Major Companies Covered in this report:- Fujian Fukang Pharmaceutical Pucheng Chia Tai Biochemistry

Request For Report Sample @ http://www.marketsplanet.com/global-chlortetracycline-hydrochloride-market-outlook-2017-2022/#ert_pane1-3

The analysis on Chlortetracycline Hydrochloride industry is provided including the up and down stream industry also with the major market players., Chlortetracycline Hydrochloride industry competitive landscape analysis.

Second, Chlortetracycline Hydrochloride industry manufacturing process, cost structure and major plants distribution is conducted for Chlortetracycline Hydrochloride market. This report Worldwide Chlortetracycline Hydrochloride Market 2017 also states major market data like capacity, gross margin, supply, price, revenue, import/export, consumption and Chlortetracycline Hydrochloride markets growth rate by regions (Europe, North America, South America, Asia, China and ROW), as well as other regions can be added in Chlortetracycline Hydrochloride Market area.

Then, the report focuses on global Chlortetracycline Hydrochloride market key players with information such as company profiles, contact information with product picture as well as specification.

DO inquiry before buying : http://www.marketsplanet.com/global-chlortetracycline-hydrochloride-market-outlook-2017-2022/#ert_pane1-2

Related information to Chlortetracycline Hydrochloride market- Capacity, Production, Capacity Utilization Rate, Price, Revenue, Cost, Gross and contact information. Also includes Chlortetracycline Hydrochloride industrys Upstream raw materials, equipment, Manufacturing and downstream industry consumers analysis is also carried out. Whats more, the Chlortetracycline Hydrochloride market development trends and Chlortetracycline Hydrochloride industry marketing channels are analyzed.

Finally, worldwide Chlortetracycline Hydrochloride market report is a valuable source of guidance for manufacturers, suppliers, distributors, customers, investors and individuals who have interest in this market.

About Us

Markets Planet offer reports from top publishers and update to serve you with immediate on-line access to professional insights on global industries, companies, products, and trends. Customers can buys different reports across various categories such as Chemical and Material, Biotechnology, Healthcare, Food and beverages, Automobile and various sectors. Our Website offers safe and secure online ordering experience, convenient payment options.

Contact US:

Frank Valadez Director of Business Development Website: http://www.marketsplanet.com Email: sales@marketsplanet.com

See the article here:
Chlortetracycline Hydrochloride Market 2017 Fujian Fukang Pharmaceutical, Pucheng Chia Tai Biochemistry - TechAnnouncer (press release)...

Anatomy of a Disney musical: Composer reveals process of creating iconic songs – ABC Online

Posted April 17, 2017 14:25:39

You probably don't know Alan Menken's name, but you do know his songs.

The acclaimed composer and songwriter is the hidden face behind some of Disney's most iconic musicals, including Beauty and the Beast, The Little Mermaid and Aladdin.

His body of work has earned him eight Oscars and 16 Golden Globes, and he's not done yet.

Mr Menken is currently in Australia for the premiere of the stage musical of Aladdin and will head home soon to work on the upcoming live action film version of the story.

So how does he create a Disney song? And what is the process for bringing a fledgling idea all the way to the big screen?

The first thing to know is that for most Disney animations the musical dramatists aka the songwriters are brought in by the studio first.

"That's something people don't know," Mr Menken told ABC News Breakfast.

"Disney will say, 'We want to tell this story' and then we say, 'OK, how do we do it?'.

"Generally you go from the basic story, to the basic structure of telling the story, to what musical style you're going to use to tell the story with, where the songs lie in that structure, then one by one tackle those songs."

Once the musical dramatists have those key song ideas in place, then the script and the story board is put together.

Then it's up to Mr Menken and the songwriters to work with the animation team to bring the songs to life.

The musical number A Whole New World was a hit on the 1992 Aladdin cartoon and went on to win the Academy Award for best original song as well as the Grammy for song of the year.

When it came to creating that song, Mr Menken said the music came first, then the lyrics, and then finally a discussion was had about the visuals.

"We ask: Is it going to be a montage? Are they going to sing to each other? What are we seeing visually in it?"

"And it's a collaboration again with the animators about what is actually happening [on screen]."

According to Mr Menken, a good song should combine with good visuals to hold the film together.

He said that while the composer and animators almost always collaborated well, sometimes their focus would be in different areas.

"In animation sometimes they'll be concentrating on a visual they really want to do and we'll be concentrating on a plot point we really want to push forward in order to support a song and there can be a little bit of creative collaboration.

"It's almost never contentious.

"There are also times when I'll say, 'You know what? We need this score and this project needs this kind of song'.

"And then we'll say, 'OK we're going to write that song and then once that's done you look at that and come back about how you're going to alter the visuals'."

A range of live action musical remakes of the original films have been coming out in recent years and include some of the original songs and many more are due for release, including Aladdin and The Lion King.

But after 50 years in the business Mr Menken has learnt a key lesson:

Having written more than 40 musicals Mr Menken has developed a pretty good feel for the business.

"I invite opinions but I have a pretty good sense of when it's right," he said.

"But I learnt a long time ago never to get invested in any song that I write.

"Because it's not a matter of the quality, it's simply about the nature of the song and whether it really hits the sweet spot for the people you're collaborating with."

This professional distance means that despite the awards, Mr Menken tries not to celebrate or mourn any of his songs too much.

"For me, you just keep writing new ones and when people like it, hey be grateful for it," he said.

And when it comes to seeing his musical numbers on the big screen for the first time?

"I feel good. I feel like I've done my job."

It's all about hitting that sweet spot, according to Mr Menken, even if he can't always predict what that will be.

"I've had songs that I thought were kind of a dumb song, but it just hit the sweet spot," he said.

"Like there was a song in [2010 animated film] Tangled called I Got A Dream.

"People love that song, but to me it's like, 'Oh my God it's a dumb song, but it works'."

More recently, Mr Menken has been tasked with writing new songs for classic Disney stories.

He collaborated on this year's live action Beauty and the Beast and wrote three new songs that fleshed out the new adaptation.

He said he wasn't upset if some fans of the original didn't immediately warm to the additions.

"I know that it will grow over time and the movie holds together," he said.

"And if the movie holds together the songs are doing their job.

"I liken myself to being an architect. I design structures that others will build and live in."

Topics: music, opera-and-musical-theatre, film-movies, australia

Original post:
Anatomy of a Disney musical: Composer reveals process of creating iconic songs - ABC Online